<?xml version="1.0" encoding="UTF-8"?>
<p id="p0070">Nevertheless, based on limited available evidences to date, and given the prevailing pandemic of COVID-19, some of the institutions and or organizations have already recognized the utility of chloroquine and HCQ [
 <xref rid="bib20" ref-type="bibr">20</xref>]. The expert consensus from the Department of Science and Technology and Health Commission of Guangdong province published on 20th February (based on 
 <italic>in vitro</italic> evidence and still unpublished clinical experience) chloroquine phosphate tablet at a dose of 500 mg twice per day for 10 days for patients diagnosed as mild, moderate and severe cases of SARS-CoV-2 pneumonia in the absence of contraindication to the drug [
 <xref rid="bib21" ref-type="bibr">21</xref>]. A Central Clinical Task Force from Korea who have treated 27 cases of COVID-19 recommend using lopinavir 400mg/Ritonavir 100 mg BID or Chloroquine 500 mg orally per day or Hydroxychloroquine 400 mg orally per day for 7–10 days, in moderate to severe case of COVID-19 [
 <xref rid="bib22" ref-type="bibr">22</xref>]. Similarly, The Dutch Center of Disease control in a public document on its website, also suggested the use of chloroquine in those having severe COVID-19 infection admitted in the intensive care unit [
 <xref rid="bib23" ref-type="bibr">23</xref>]. 
 <xref rid="tbl2" ref-type="table">Table 2</xref> summarizes the recommendation and dosing from all the various groups [
 <xref rid="bib21" ref-type="bibr">[21]</xref>, 
 <xref rid="bib22" ref-type="bibr">[22]</xref>, 
 <xref rid="bib23" ref-type="bibr">[23]</xref>, 
 <xref rid="bib24" ref-type="bibr">[24]</xref>, 
 <xref rid="bib25" ref-type="bibr">[25]</xref>, 
 <xref rid="bib26" ref-type="bibr">[26]</xref>, 
 <xref rid="bib27" ref-type="bibr">[27]</xref>, 
 <xref rid="bib28" ref-type="bibr">[28]</xref>].
</p>
